As you may know, Sin Hang Lee, MD, director of Milford Molecular Diagnostics Laboratory, and developer of our own TeaForHealth®, is also a well-known cancer and molecular pathologist specializing in screening women’s infections caused by human papillomavirus (HPV), Chlamydia trachomatis (the most common and treatable sexually transmitted disease), and Neisseria gonorrhoeae (gonorrhea). Dr. Lee patented the first FDA-approved histochemical estrogen receptor assay for breast cancers and, based on his research, has requested the FDA to revise the classification and use direction of the current FDA-approved HPV test to reduce the excessive unnecessary harmful colposcopic cervical biopsies on American women.
Dr. Lee has also challenged the safety of the human papillomavirus (HPV) vaccines, Gardasil® and Cervarix®.
Cervical Pap smear cytology, HPV, Chlamydia trachomatis and Neisseria gonorrhoeae screens are part of good women’s health care offered routinely by all practicing gynecologists in the United States. But, Dr. Lee’s new CLIA-certified laboratory tests differ from those currently offered by other commercial laboratories in that his lab results are validated by Sanger sequencing, presently the only guaranteed quality of all DNA tests.
Recently, the Centers for Medicare & Medicaid Services has granted Dr. Lee’s laboratory a permit to perform his specially developed BRCA1 and BRCA2 Ashkenazi Jewish founder mutations screening designed to evaluate the risk of hereditary breast cancer and ovarian cancer for women who may have Ashkenazi ancestry. This permit allows Dr. Lee’s laboratory to test for BRCA1 and 2 mutations on one Pap cytology sample along with HPV, Chlamydia trachomatis and Neisseria gonorrhoeae. As a result of his research, the costs of these tests are markedly reduced and yet are extremely accurate. In the past, many of these tests have been expensive and often somewhat unreliable.
For more information, visit the website of Milford Molecular Diagnostics Laboratory www.dnalymetest.com
Dr. Lee has also allowed a Special Discount to our TeaForHealth customers, their family and friends. A special order form can be obtained on our website www.TeaForHealth.com.
The four individual tests, all non-invasive, are as follows:
BRCA 1&2 Founder Mutation Panel hereditary
This is a one-time non-invasive DNA test, using routine pap smear samples, that predicts the probability of a patient ever developing hereditary breast and ovarian cancers. The intended use of the test for the three BRCA1 and BRCA2 founder mutations is to screen women with a family history of breast, ovarian, tubal, or peritoneal cancer or Ashkenazi Jewish ancestry. Until now, such DNA testing had a very high cost and was beyond the reach of many. The obvious reason for testing is the advantage of early “enhanced surveillance” by your health care provider, as advised by ACOG https://www.acog.org/Patients/FAQs/BRCA1-and-BRCA2-Mutations
HPV DNA detection
The purpose of this test is to determine the presence of HPV in the uterine cervical cells. Finding the same “high risk” HPV genotype in at least two consecutive samples taken more than 6 months apart with Pap cytology abnormalities indicates persistent HPV infection which may lead to cervical cancer. HPV vaccination of a woman already infected with a vaccine-relevant HPV genotype may accelerate cervical cancer development.
Chlamydia trachomatis (STI)
The purpose of this non-invasive test is to determine the presence of Chlamydia infection.
Neisseria Gonorrhoeae (gonorrhea)
The purpose of this non-invasive test is to determine the presence of Gonorrhea.
We congratulate Dr. Lee on his success and we are thankful that he supports our cause.